Hepatocyte Nuclear Factor 1a (HNF1a) and Hepatocyte Nuclear Factor 4a (HNF4a) are two liverenriched transcription factors coexpressed in speci®c tissues where they play a crucial role through their involvement in a complex cross-regulatory network. HNF1a down regulates HNF4a-mediated activation of transcription via a direct protein±protein interaction. Here we show that HNF4a enhances the transcriptional activity of HNF1a in a DNA binding independent manner, thus indicating that it behaves as a HNF1a coactivator. Using mutations in the ligand binding domain (LBD) of HNF4a, we con®rmed the involvement of the Activation Function 2 module and demonstrated the requirement of the integrity of the LBD for the interaction with HNF1a. Moreover, we show that HNF4a cooperates with p300 to achieve the highest HNF1a-mediated transcription rates. Our ®ndings highlight a new way by which HNF4a can regulate gene expression and extend our knowledge of the complexity of the transcriptional network involving HNF4a and HNF1a.
INTRODUCTION
Hepatocyte Nuclear Factor 1a (HNF1a) and Hepatocyte Nuclear Factor 4a (HNF4a) are two liver-enriched transcription factors that are also expressed in kidney, intestine and endocrine pancreas (1) . They are involved in complex crossregulatory networks that determine the phenotype of hepatocytes and pancreatic b-cells (1±3). HNF1a is a homeodomaincontaining transcription factor (1) whereas HNF4a belongs to the hormone nuclear receptor superfamily (4) . Both transcription factors are highly conserved during evolution (4, 5) . HNF1a and HNF4a directly modulate the expression of a large number of genes (4, 6, 7) . They can also modulate transcription indirectly through the above mentioned transcription factor network, including a HNF1a-mediated negative regulation of genes activated by HNF4a (8, 9) . The roles of these transcription factors in vivo have been con®rmed by defects linked to the invalidation of their genes in mice (10±14). Further underscoring the importance of these transcription factors, mutations in HNF1a and HNF4a genes have been identi®ed in patients with Maturity Onset Diabetes of the Young, MODY3 and MODY1, respectively (15, 16) . MODY1 and MODY3 mutations result in loss of function of these transcription factors (17) . Moreover, it has been reported that expression of a HNF1a dominant negative mutant linked to MODY3 led to an impaired function of pancreatic b-cells (18) .
HNF1a contains two domains involved in DNA binding (an atypical homeodomain and a POU-like domain), an N-terminal dimerization domain and a C-terminal transactivation domain (1) . Several proteins interact with various HNF1a domains and play crucial roles in HNF1a function. DcoH (Dimerization Cofactor of HNF1), is a small protein, which binds to the HNF1 dimerization domain and is involved in dimer stabilization (19) . The ability of various HNF1a domains to interact with multiple coactivators allows formation of a platform for recruitment of a transcriptional complex, leading to a strong enhancement of transcription. CBP/p300 interacts with both the DNA binding domain and the activation domain of HNF1a while P/CAF, SRC-1 and RAC3 interact with the HNF1a activation domain (20, 21) . Each of these coactivators can independently increase activation of transcription by HNF1a. In addition, they cooperate with each other to further enhance the HNF1a-mediated activation of transcription (21) . HNF1a can also interact with GATA 4, GATA 5 and Cdx-2 transcription factors (22) . The interactions between HNF1a, GATA5 and Cdx-2 lead to a cooperative enhancement of HNF1a-mediated activation of transcription (22) . A synergy between HNF1a and neurogenin 3 was also recently reported (23) . HNF1a down regulates HNF4a-mediated activation of transcription via a direct interaction of these transcription factors (8, 9) .
In this work, we show that HNF4a enhances the transcriptional activity of HNF1a, and that the cooperation between both factors can be further enhanced by p300 recruitment.
MATERIALS AND METHODS

DNA constructs
Plasmids pcDNA3 HNF4a2 and pcDNA3 HNF4a2-E276Q were previously described (24) . Plasmid pcDNA3 HNF4a2-D126Y was described by Oxombre et al. (25) . Plasmids *To whom correspondence should be addressed. Tel: +33 3 20 62 69 51; Fax: +33 3 20 62 68 84; Email: blaine@lille.inserm.fr pcDNA3 HNF4a2-E262A and pGEX2TK HNF4a2 were described by Eeckhoute et al. (26) . Plasmids pcDNA3 HNF1a and pcDNA3 HNF1a-P291fsinsC, here named HNF1a-DAD, were generous gifts from Drs M. Yaniv and A. Abderrahmani, respectively. Plasmids pcDNA3 HNF4a2-A223F and pcDNA3 HNF4a2-AF2mut were obtained by site-directed mutagenesis using the QuickChangeÔ kit (Stratagene) to introduce the A223F or the three mutations E363K, L365Q and L366Q, respectively. Plasmid pM3-VP16 was from Clontech and pcDNA3-RXRb encoding the full-length human RXRb was a generous gift from Dr R. Polakowska. Plasmid pGEX2TK HNF1a was prepared by a strategy identical to that used for cloning pGEX2TK COUP-TFII (24) by inserting a PCR fragment encompassing the human HNF1a cDNA. Plasmid pCMVb-NHA p300, PGEX2TK p300(1±595), PGEX2TK p300(340±528) and PGEX2TK p300(1572±2370) were kindly provided by Dr S. R. Grossman. Expression plasmids for VP16, Np300-VP16 and Cp300-VP16 were gifts from Dr D. Hum (27) . Plasmid pGL3 (±96/+11) LPK was a generous gift from Dr M. VasseurCognet (28) . Plasmid pGL3 (±341/+183) human HNF1a was a gift from Dr G. Bell. Plasmid (GAL4)x5 TATA Luc was described by Chang and Gralla (29) . Plasmid pGL3 HNF1a-TATA-Luc was cloned by inserting a double-stranded oligonucleotide encompassing the HNF1a binding site (±56/ ±35) of the SRC promoter into the SacI/NheI sites of the pGL3 basic vector in which the TATA box of the adenovirus major late promoter had been previously cloned as described by Suaud et al. (24) . All constructs were veri®ed by DNA sequencing.
GST pull-down assays
GST pull-down assays were performed as described previously (24) using [ 35 S]methionine-labelled in vitro synthesized HNF1a or HNF4a and bacterially expressed GSTfusion proteins indicated in legends to ®gures.
Cell culture and transient transfection assays
HeLa cells (5.5 Q 10 4 cells per 24-well dish) were grown and transfected as described by Eeckhoute et al. (30) with plasmid amounts indicated in ®gure legends. Luciferase activities were measured using the Bright-Glo Luciferase assay system (Promega).
Western blotting
Western blotting performed from whole-cell extracts and using the a455 HNF4a antiserum was carried out as indicated by Eeckhoute et al. (26) .
Data analysis
Statistical analyses were based on Student's t-test for unpaired data using Prism software. Statistical signi®cance was set at ***P < 0.001, **P < 0.01 and *P < 0.05.
RESULTS
Enhancement of HNF1a-mediated activation of transcription by HNF4a
HNF1a and HNF4a can positively regulate one another's expression in cell types that endogenously express these two factors (3, 6) . To avoid any interference with the endogenous proteins, the effect of HNF4a on the transactivation activity of HNF1a was analysed in HeLa cells. The experiments were performed on a synthetic promoter consisting of one HNF1a binding site located upstream of the TATA box (HNF1a-TATA promoter) and on the natural liver pyruvate kinase promoter (±96/+11) LPK containing one HNF1a binding site (site L1, position ±96/±72) but lacking the HNF4a response element (28) . As expected, both promoters were activated by HNF1a but not by HNF4a (Fig. 1A and B) . Cotransfection of HNF1a and HNF4a resulted in a marked increase in the HNF1a-mediated activation of these promoters (2.8-and 3.4-fold activation of the synthetic and LPK promoters, respectively) (Fig. 1A and B) . The enhancement of the HNF1a activity was not impaired when introducing the D126Y mutation in HNF4a, which signi®cantly decreases its DNA binding and transactivation activities (25) (data not shown), thus con®rming that the synergy between HNF1a and HNF4a does not require the DNA binding-dependent activities of HNF4a ( Fig. 1A and B ). This induction was not an artefact linked to expression of a protein since cotransfection of an unrelated factor failed to enhance the HNF1a-mediated activation of transcription (compare the second and last columns in Fig. 1A and B) .
To control the possibility that HNF4a does not act as a transcriptional partner of another transcription factor, we analysed the effect of HNF4a on the VP16 activation domain fused to the GAL4 DBD (construct GAL4-VP16). HNF4a was unable to enhance the VP16-mediated activation of transcription ( Fig. 1C) , thus indicating the selectivity of the cooperation between HNF4a and HNF1a.
As predicted from the results of Ktistaki and Talianidis (9), we observed that full-length HNF1a and HNF4a physically interact (Fig. 1D) . Interestingly, pull-down experiments also showed that HNF1a lacking its activation domain (HNF1a-DAD) ef®ciently interacted with HNF4a (Fig. 1D ). This result indicates that the sequence 1±291 of HNF1a, containing the dimerization and DNA binding domains, is able to interact with HNF4a. This prompted us to investigate whether coexpression of HNF4a and HNF1a-DAD could activate the HNF1a-TATA promoter. Despite their ef®cient interaction, HNF1a-DAD and HNF4a were unable to activate transcription ( Fig. 1E) , thus indicating that cooperation between HNF1a and HNF4a requires the HNF1a activation domain.
AF2 is not the only sequence within the HNF4a LBD required for interaction and cooperation with HNF1a
The repressive action of HNF1a on HNF4a was unambiguously shown to require the HNF4a LBD (9). However, using truncated fragments of HNF4a, Ktistaki and Talianidis mapped the sequence involved in the interaction with HNF1a between residues 337 and 368, leading to the conclusion that the HNF4a AF2 activation function is necessary and suf®cient for interaction with HNF1a (9). In fact, this sequence does not contain solely the AF2 (sequence 358±366 corresponding to helix 12 of the LBD), but also a fragment forming part of the large helix termed H10±H11, according to conventional nomenclature (31) . Indeed, H10 and H11 are contiguous in HNF4a and form a helix that plays a key role in HNF4a function (31) . Furthermore, the integrity of this helix is crucial for protein conformation (32) . These Nucleic Acids Research, 2004, Vol. 32, No. 8 2587 recent ®ndings begged a re-evaluation of the HNF4a sequence involved in interaction with HNF1a. Using full-length HNF4a, we analysed the effects of point mutations located in the HNF4a LBD ( Fig. 2A) on the interaction and cooperation with HNF1a. The E262A mutation was shown to affect HNF4a dimerization (26) . The E276Q mutation does not alter the intrinsic HNF4a transcriptional activity but impairs recruitment of HNF4a transcriptional partners (24, 33) . Owing to the bulky side chain of phenylalanine, the A223F mutation was hypothesized to affect occupancy of the ligand binding pocket by fatty acids that act as structural cofactors rather than as conventional ligands (31) . Accordingly, A223F mutation mildly impaired HNF4a transcriptional activity and interaction with coactivators (data not shown). In the AF2 module, the acidic group of the amino acid residue side chain at position 363 and the hydrophobic nature of the amino acid residue side chain at position 365 are strictly conserved and play a key role in nuclear receptor function (34) . Residue L366 is also important since the L366Q mutation alters HNF4a transcriptional activity (35) . Pulldown assays showed that introducing three mutations E363K, L365Q and L366Q in the AF2 (HNF4a-AF2mut construct) altered interaction between HNF4a and HNF1a (Fig. 2B) . Note however that the decrease in interaction was mild. This result con®rms the involvement of the AF2 in the interaction between HNF1a and HNF4a but indicates that this module is not the unique sequence required for interaction between these proteins. Interaction with HNF1a was also signi®cantly decreased by the A223F and E276Q mutations while mutation E262A had no effect (Fig. 2B) . Consistent with data from pulldown assays, the HNF4a-mediated enhancement of HNF1a-dependent transcriptional activation of the (±96/+11) LPK promoter was not impaired by the E262A mutation but was signi®cantly decreased with the mutants A223F, E276Q and HNF4a-AF2mut (Fig. 2C) . We controlled so that mutant and wild-type HNF4a were expressed at a similar level in transfected cells as shown in Figure 2D for mutants A223F and HNF4a-AF2mut and in (24, 26) for the mutant E276Q and E262A, respectively. It appears therefore that the interaction and cooperation between HNF4a and HNF1a depend on both the AF2 module (helix 12) and the integrity of the HNF4a LBD.
HNF4a cooperates with the coactivator p300 to enhance HNF1a transcriptional activity Because CBP/p300 are key coactivators of HNF1a, we hypothesized that cooperation between HNF4a and HNF1a could involve p300. In the absence of HNF1a, the coactivator p300 alone or coexpressed with HNF4a was unable to activate the HNF1a-TATA promoter (Fig. 3A) . On this promoter, (Fig. 3A) . Note that this moderate increase is due at least in part to the low ratio of p300/HNF1a expression vectors used in our experiments (3:1) compared to that used in other studies performed on other promoters [e.g. 10:1 in Soutoglou et al. (21) ]. We have veri®ed that by using a higher ratio, we could obtain a stronger enhancement of HNF1a activity by p300 alone (data not shown). Interestingly, in the presence of HNF4a, p300 synergistically enhanced HNF1a-mediated activation of transcription: the activity of the promoter was increased 18.4-fold, which is 4.7-fold higher than the additive value for the induction of HNF1a activity by p300 and HNF4a alone (1.8 and 2.1, respectively). The marked p300-mediated enhancement of cooperation between HNF1a and HNF4a could also be observed on the (±96/+11) LPK promoter (Fig. 3B) . On both promoters, the enhanced cooperation between HNF1a and HNF4a was signi®cantly impaired by mutations in the HNF4a AF2 module (Fig. 3A and B). These results strongly argue for the involvement of HNF4a in the p300-mediated activation of these promoters despite the absence of HNF4a response element in their sequences. The result obtained with the HNF4a-AF2mut led us to investigate whether mutations in AF2 affect p300 binding. Pull-down experiments clearly showed a much weaker interaction of p300 with HNF4a-AF2mut than with wild-type HNF4a (Fig. 3C ). This result is in line with our previous observation that deletion of the AF2 resulted in a decrease in interaction (about 70%) between HNF4a and p300 (33) . Therefore, we cannot exclude that the impaired cooperativity of HNF4a-AF2mut was also due to reduced p300 recruitment. Because it has been documented that HNF4a and CBP/p300 form a transcriptionally active complex (36), we veri®ed whether in our experimental conditions this complex was suf®cient to achieve the strong cooperation. This question was addressed by the use of human HNF1a promoter containing a HNF4a response element but lacking a HNF1a binding site. Using the same p300/HNF4a expression vector amounts used in Figure 3A and B, cotransfection of p300 failed to strongly enhance the HNF4a-mediated activation of transcription (Fig. 3D ). It appears therefore that the strong activation of transcription observed in Figure 3A and B requires a ternary complex including HNF1a, HNF4a and p300.
With the aim to investigate the mechanism underlying the p300-mediated enhancement of the cooperation between HNF1a and HNF4a, we surveyed the p300 domains involved in interactions with these transcription factors. Using a double hybrid approach, it was previously shown that the sequences 180±662 and 1818±2079 of p300 interact with the HNF1a transactivation domain (20) . Using GST pull-down assays, we mapped more precisely the amino-terminal sequence of p300 involved in interaction with full-length HNF1a between residues 340 and 528 (Fig. 4B) . We also con®rmed that fulllength HNF1a interacts with the carboxy-terminal region of p300 (Fig. 4C) . We have previously shown the ability of HNF4a to interact with the amino-terminal domain of p300 (33) . HNF4a also interacted with the p300 carboxy-terminal region as shown in Figure 4C . The presence of multiple interaction surfaces between these proteins led us to analyse the effect of HNF4a on the recruitment of the amino-and carboxy-terminal regions of p300 to HNF1a. The strategy consisted of determining whether HNF4a affects the cooperation between HNF1a and the amino-or carboxy-terminal fragments of p300 fused to the VP16 activation domain named Np300-VP16 and Cp300-VP16, respectively (Fig. 4A) . Expression of the VP16 activation domain affected neither the basal activity of the promoter nor its activity in the presence of expression vectors for HNF1a alone or together with HNF4a (Fig. 4D, left part) . Expression of Np300-VP16 failed to affect the basal activity of the promoter and the HNF1a-mediated activation of this promoter (Fig. 4D,  middle) . Similar results were obtained with expression of Cp300-VP16 (Fig. 4D, right) . Conversely, in the presence of both HNF1a and HNF4a, Np300-VP16 and Cp300-VP16 markedly enhanced the promoter activity (Fig. 4D) . These results indicate that, in a cellular context, p300 recruitment by the HNF1a±HNF4a complex can be mediated through both its amino-and carboxy-terminal regions and reinforce data obtained in Figure 3 suggesting that HNF4a improves p300 recruitment to a promoter containing a HNF1a binding site (Fig. 4E) .
DISCUSSION
It has been previously shown that HNF1a acts as a repressor of HNF4a-mediated activation of transcription (8, 9) . In this study, we show that HNF4a can serve as a coactivator for HNF1a since HNF4a is able to enhance HNF1a activity in a DNA-binding independent manner. A synergy between HNF1a and HNF4a can be inferred from data obtained in undifferentiated Caco-2 cells on a promoter containing binding sites for these two HNFs. Since mutation of the HNF4a binding site did not affect this synergy, the authors suggested that this effect probably did not involve HNF4a DNA binding (37) . In light of our results, these data can now most probably be explained by the ability of HNF4a to directly act as a HNF1a coactivator. Analysis of the physiological role of this HNF4a coactivator function in cell types that endogenously express HNF1a and HNF4a cannot be realized by conventional targeting of HNF4a expression since HNF4a also positively regulates HNF1a expression. Therefore, this concern will ®rst require development of an experimental model that permits to distinguish between HNF4a effects linked to regulation of HNF1a expression on one hand and to regulation of HNF1a transcriptional activity on the other hand (Fig. 5) .
Interplays between two transcription factors in both activation and repression of transcription have already been documented. Indeed, cross-talk between HNF6 and HNF3b, two other liver-enriched transcription factors, also results in opposite effects on the activities of these proteins (38) .
Despite their ef®cient interaction, HNF4a and HNF1a lacking its activation function (HNF1a-DAD) were unable to cooperate. Such a behaviour is reminiscent of that of CBP and P/CAF with HNF1a (1±280) (21) . Only the simultaneous overexpression of CBP and P/CAF together with that of the truncated HNF1a could activate transcription (21) . This points to a critical role for the HNF1a activation domain, which could be the recruitment of other required coactivators and/or stabilization of the transcriptional complex recruited by HNF1a. or Np300-VP16 (middle) and VP16 or Cp300-VP16 (right) expression plasmids. In each case, the total amount of transfected DNA was kept constant using empty pcDNA3. Fold induction refers to the basal activity of the promoter (left columns). Results are means T S.E. of at least three experiments performed in triplicate. (E) Mechanisms by which HNF4a could enhance HNF1a transcriptional activity. The amino-and/or carboxy-terminal domains of p300 can be involved in p300-mediated activation of transcription. HNF4a could enhance p300 recruitment through direct binding to these p300 fragments and/or through an indirect effect on the HNF1a±p300 interactions. HNF4a could also help recruitment of other coactivators to the transcriptional complex.
Nucleic Acids
Our results indicate that the HNF4a AF2 is involved in interaction with HNF1a, but also that other regions of the HNF4a LBD are required for full interaction between these proteins. Ktistaki and Talianidis previously stated that the HNF4a AF2 is suf®cient for interaction with HNF1a (9) . The discrepancy between their conclusion and our results is likely explained by the fact that these authors used deletion of a fragment (residues 337±368), which includes not only the AF2 but also part of the large helix H10±H11, the integrity of which has meanwhile been shown to be crucial for the protein conformation (32) . We observed that two-point mutations in the HNF4a LBD, A223F and E276Q, signi®cantly decreased interaction and cooperation with HNF1a thus demonstrating that the integrity of the HNF4a LBD is required for the synergy with HNF1a.
The similarity of phenotypes exhibited by diabetic patients carrying MODY1 and MODY3 mutations has been ascribed to the mutual control of transcription of HNF1a and HNF4a. The ability of HNF4a to serve as an HNF1a coactivator could provide an additional explanation to the closely related phenotypes of these MODY forms of diabetes. Impairment of interaction and of enhancement of HNF1a transcriptional activity by the HNF4a E276Q mutation may be physiologically relevant since this mutation is correlated with MODY1. Unfortunately, the low transfection ef®ciency and the presence of large amounts of endogenous HNF4g in pancreatic b-cells prevented us from analysing the effects of this mutation on the synergy between HNF4a and HNF1a in these cells.
Our results support a model that involves the combined action of HNF4a and the coactivator p300 to achieve the highest rate of transcription mediated by HNF1a. Our results also strongly suggest that HNF4a improves p300 recruitment. The synergy between HNF4a and p300 may be mediated in two ways. The ®rst involves simultaneous interactions of HNF4a and p300 with HNF1a (Fig. 4E) . In this case, HNF4a could indirectly improve HNF1a±p300 interaction through induction of a HNF1a conformational change. Such a mechanism is reminiscent of that of the CBP-mediated improvement of the interaction between HNF1a and P/CAF (21) . Similarly, upon docking to PPARg, PGC-1 undergoes a conformational change that permits binding of SRC-1 and p300 (39) . The second involves docking of p300 by HNF4a, which is bound to HNF1a (Fig. 4E) . The recruitment of p300 to the HNF1a±HNF4a complex could be mediated by its amino-and/or carboxy-terminal regions, which contain the C/H1 and C/H3 domains, respectively. These domains are known to be involved in protein±protein interactions (40) . The presence of multiple interaction surfaces in HNF1a, HNF4a and p300 most probably facilitates formation of a ternary complex formed with these proteins (Fig. 4E) . The remaining synergy between HNF1a and HNF4a after mutations in the HNF4a AF2 (Fig. 3 ) may be accounted for by the ability of p300 to interact and activate the HNF4a AF1 (33, 41) and by the fact that the two above mentioned mechanisms may not be mutually exclusive.
In conclusion, our results highlight a new way by which HNF4a can regulate gene expression. HNF4a not only directly binds to promoters but also, through interaction with other transcription factors already bound to DNA, can facilitate coactivator recruitment to further enhance transcription. Recently, it has been shown that HNF4a also serves as coactivator for Sterol Regulatory Element-Binding protein-2 (42) . Furthermore, our results yield insights into a higher complexity of the transcriptional network and on the primordial relationship between HNF1a and HNF4a (Fig. 5) . In the regulatory loop between HNF1a and HNF4a, HNF4a can activate both HNF1a expression and transcriptional activity. In contrast to these additive processes, the negative effect of HNF1a on HNF4a transcriptional activity can attenuate the HNF1a-mediated activation of expression. These regulatory feedback mechanisms will have to be taken into account considering that HNF1a and HNF4a are involved in a large diversity of pathways controlling function of multiple organs, notably liver and endocrine pancreas.
